Given potential resistance in the clinical setting, John M. Kane, MD, explains the logistics of switching a patient with schizophrenia to a long-acting injectable formulation.
- 5 жыл бұрын
Schizophrenia: Switching to a Long-Acting Injectable
- Рет қаралды 1,653
Пікірлер: 2